Bruker (NASDAQ:BRKR) Shares Gap Up on Strong Earnings

Bruker Corporation (NASDAQ:BRKR)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $38.01, but opened at $41.87. Bruker shares last traded at $41.5150, with a volume of 333,197 shares changing hands.

The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $796.11 million. During the same period in the previous year, the firm earned $0.47 earnings per share. Bruker’s revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s payout ratio is presently -133.33%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. UBS Group restated a “neutral” rating and issued a $49.00 target price on shares of Bruker in a report on Friday, February 13th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a report on Thursday, February 12th. TD Cowen upgraded shares of Bruker to a “hold” rating in a report on Monday, April 13th. Citigroup lowered their target price on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Finally, Barclays lowered their target price on shares of Bruker from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Bruker has an average rating of “Hold” and a consensus target price of $49.38.

Insider Activity at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

A number of large investors have recently modified their holdings of the stock. Allworth Financial LP grew its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Bruker by 6.7% in the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after buying an additional 380 shares in the last quarter. Linden Thomas Advisory Services LLC grew its stake in shares of Bruker by 2.1% in the third quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company’s stock valued at $639,000 after buying an additional 396 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Bruker by 1.4% in the third quarter. Arizona State Retirement System now owns 31,369 shares of the medical research company’s stock valued at $1,019,000 after buying an additional 435 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Up 11.5%

The firm has a market capitalization of $6.45 billion, a PE ratio of -283.17, a P/E/G ratio of 2.18 and a beta of 1.12. The firm’s 50 day moving average price is $37.13 and its two-hundred day moving average price is $41.99. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.